5
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
200 recruiting
5
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Elevar Therapeutics, Inc. is a company with 5 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| adenoid cystic carcinoma | Rivoceranib | Des.TrialAppr. |
| cholangiocarcinoma | N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride | Des.TrialAppr. |
| gastric cancer | apatinib mesylate | Des.TrialAppr. |
| hepatocellular carcinoma | rivoceranib | Des.TrialAppr. |
| ovarian cancer | paclitaxel, micellar | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
43
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
43
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio